Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
We prospectively evaluated the effects of celecoxib (CEL) on the gastrointestinal (GI) tract of rheumatoid arthritis (RA) patients with endoscopically identified GI mucosal injury after therapeutic switching from the long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Upper GI endoscopy was performed on RA patients who had been treated with NSAIDs for ≥3 months. GI mucosal injury was evaluated according to the modified LANZA score. Patients with mucosal injury without ulcers were switched from NSAIDs to CEL, while those with ulcers were switched to CEL with famotidine after ulcer healing. At week 16 of treatment, GI mucosal injury was endoscopically revaluated. An efficacy analysis was performed before therapeutic switching and at 8 and 16 weeks post-switching. Endoscopic analysis revealed GI mucosal injury, including six ulcers, in 45 of the 82 patients (54.9%). Sixteen weeks after switching to CEL, LANZA scores were significantly improved [2.1 ± 0.8 (pre-switching) vs. 1.6 ± 1.3, P = 0.0073] in patients with LANZA scores of 1, 2, or 3 (n = 35). The Disease Activity Score using 28 joint counts (DAS28) [erythrocyte sedimentation rate item score (ESR4) (P = 0.0257) and C-reactive protein item score (CRP4) (P = 0.0031)] was also significantly improved by week 16. Based on these results, we conclude that preexisting NSAID-induced upper GI injury is improved following therapeutic switching to CEL without any reduction in analgesic efficacy.
- Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120:594–606. CrossRef
- Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA, Laine L. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337–44. CrossRef
- Shiokawa Y, Nobunaga M, Saito T, Asaki S, Ogawa N. Epidemiology study on upper gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs (in Japanese). Ryumachi. 1991;31:96–111.
- Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(1B):31S–8S. CrossRef
- Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1888–99. CrossRef
- Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–96.
- Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9. CrossRef
- Tomita T, Ochi T, Sugano K, Uemura S, Makuch RW. Systematic review of NSAID-induced adverse reactions in patients with rheumatoid arthritis in Japan. Mod Rheumatol. 2003;13:143–52.
- Rahme E, Toubouti Y, Hunsche E. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Qubec, Canada. Rheumatology. 2006;45:903–10. CrossRef
- Langman M, Kahler KH, Kong SX, Zhang Q, Finch E, Bentkover JD, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf. 2001;10:517–24. CrossRef
- Sift R, van Staa TP, Abenhaim L, Ebner D. A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiol Drug Saf. 1997;6:263–8. CrossRef
- Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol. 1992;45:187–95. CrossRef
- García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132:498–506. CrossRef
- García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72. CrossRef
- Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075–8. CrossRef
- Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921–8. CrossRef
- Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019–27. CrossRef
- Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106–11. CrossRef
- Wolfe F, Michaud K, Burke TA, Zhao SZ. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal anti-inflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol. 2004;31:355–8.
- Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf. 2004;13:277–87. CrossRef
- Harley C, Wagner S. Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Manag Care Interface. 2003;16:38–45.
- Moride Y, Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology 2003;42[Suppl 3]:iii17–22.
- Robinson MG, Griffin JW Jr, Bowers J, Kogan FJ, Kogut DG, Lanza FL, et al. Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 1989;34:424–8. CrossRef
- Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334:1435–9. CrossRef
- Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J. 2004;329:948–52. CrossRef
- Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–55. CrossRef
- Scheilman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007;369:1580–1. CrossRef
- Chan FK, Abraham NS, Scheilman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First international working party on gastrointestinal and cardiovascular effects on nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol. 2008;103:2908–18. CrossRef
- Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16:137–62. CrossRef
- Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclooxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–6. CrossRef
- Miyake K, Ueki N, Suzuki K, Shinji Y, Kusunoki M, Hiratsuka T, et al. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther. 2005;21(Suppl 2):67–72. CrossRef
- US Food and Drug administration (FDA). Possible increased risk of bone fractures with certain antacid drugs. FDA Consumer Health Information. FDA, Washington, D.C., 2010.
- Sener G, Goren FO, Ulusoy NB, Ersoy Y, Arbak S, Dülger GA. Protective effect of melatonin and omeprazole against alendronate-induced gastric damage. Dig Dis Sci. 2005;50:1506–12. CrossRef
- Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med. 2001;161:107–10. CrossRef
- Miyake K, Kusunoki M, Shinji Y, Shindo T, Kawagoe T, Futagami S, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol. 2009;44:113–20. CrossRef
- Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation
Volume 22, Issue 3 , pp 353-362
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Cyclooxygenase-2 (COX-2) inhibitors
- Nonsteroidal anti-inflammatory drugs
- Rheumatoid arthritis
- Upper gastrointestinal mucosal injury
- Industry Sectors
- Author Affiliations
- 1. Department of Orthopaedic Surgery, Hoshigaoka Koseinenkin Hospital, 4-8-1 Hoshigaoka, Hirakata, Osaka, 573-8511, Japan
- 2. Department of Gastroenterology, Hoshigaoka Koseinenkin Hospital, Hirakata, Japan
- 3. Department of Orthopaedics, Osaka University Graduate School of Medicine, Osaka, Japan